Vitamin D level is linked to susceptibility to infections, but its relevance in candidemia is unknown. We aimed to investigate the in vivo sequelae of vitamin D 3 supplementation in systemic Candida infection. Implicating the role of vitamin D in Candida infections, we showed that candidemic patients had significantly lower 25-OHD concentrations. Candida-infected mice treated with low-dose 1,25(OH) 2 D 3 had reduced fungal burden and better survival relative to untreated mice. Conversely, higher 1,25(OH) 2 D 3 doses led to poor outcomes. Mechanistically, low-dose 1,25(OH) 2 D 3 induced proinflammatory immune responses. This was mediated through suppression of SOCS3 and induction of vitamin D receptor binding with the vitamin D-response elements in the promoter of the gene encoding interferon γ. These beneficial effects were negated with higher vitamin D 3 doses. While the antiinflammatory effects of vitamin D 3 are well described, we found that, conversely, lower doses conferred proinflammatory benefits in Candida infection. Our study highlights caution against extreme deviations of vitamin D levels during infections.
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Beyond its classical role in calcium and bone metabolism, vitamin D 3 is known to exert a protean influence on the immune system [1, 2] . One such effect described is the propensity of vitamin D 3 to skew host cytokine response away from a proinflammatory profile toward a T helper type 2 (Th2) and regulatory T-cell response [3] [4] [5] . It also limits the antigen-presenting capacity of macrophages and directs the differentiation of dendritic cells toward a more tolerogenic phenotype, inducing heightened interleukin 10 (IL-10) levels [6, 7] . With the innate and bridging adaptive immune system forming the critical frontline defense protecting the host against pathogens, it is compelling to speculate whether vitamin D may influence host susceptibility to infections. Candidemia is the fourth most common bloodstream infection (BSI) in hospitals worldwide [8] . The options of antifungal agents available are limited, and patients with Candida BSI and invasive candidiasis have mortality rates of up to 40% [9] . This is partly due to the host's inability to mount an effective immune response against the invading fungi [10] .
We had earlier investigated the role of 1,25(OH) 2 D 3 on in vitro cytokine production induced by Candida stimulation of human peripheral blood mononuclear cells (PBMCs). We found that 1,25(OH) 2 D 3 skewed cytokine response toward an antiinflammatory profile with downregulation of interleukin 6, tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ) [11] . However, the biological relevance of these effects was not known. Hence, we aim to investigate and validate the sequelae of the immunomodulatory properties of vitamin D 3 in vivo.
METHODS

Stimuli and Reagents
Candida albicans cells (SC5314) were grown overnight at 30°C in yeast extract-peptone-dextrose broth. Cells were washed twice in phosphate-buffered saline (PBS) and diluted to 5 × 10 6 microorganisms/mL. Heat-killed C. albicans blastoconidia were used at a concentration of 1 × 10 6 blastoconidia/mL. 1,25
(OH) 2 D 3 was purchased from Fluka Biochemika, Sigma-Aldrich (St. Louis, Missouri), and dissolved in absolute ethanol. The pharmaceutical preparation of 1,25(OH) 2 D 3 , Calcijex (1 µg/mL ampoule), was from Abbott Laboratories (Quebec, Canada).
Mice
Eight weeks old Balb/c mice weighing 20-24 g were infected with 2.5 × 10 5 live C. albicans (SC5314) via tail vein injection.
One hundred microliters of vitamin D 3 (Calcijex) was administered intraperitoneally from day 2 after infection at doses of 0.001 µg/kg, 0.01 µg/kg, 0.1 µg/kg, or 1 µg/kg for 3 days; 3-day administration of PBS served as a control. Weight and survival were charted daily, and the fungal burden in the kidneys was assessed 6 days after infection. The number of viable Candida organisms was determined by plating serial dilutions on Sabouraud dextrose agar plates, and the colony forming units (CFUs) were counted after incubation for 24 hours at 37°C. For the survival studies, following Candida infection (on day 0), the mice were treated from day 2 onward with the stipulated daily doses of Calcijex for either 3 days or continuously.
PBMC Isolation
Separation and stimulation of PBMCs from healthy volunteers were performed as previously described [12] . Blood specimens were collected into sodium heparin tubes (BD Vacutainer, Franklin Lakes, New Jersey) after informed consent was received. PBMCs were isolated by density centrifugation on Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden). Cells were washed, counted, and adjusted to a concentration of 5 × 10 6 cells/mL in culture medium (Roswell Park Memorial Institute 1640 medium, Dutch modification, supplemented with gentamicin, L-glutamine, and sodium pyruvate). Stimulation assays were performed in 96-well round-bottomed plates, using 100 µL of PBMCs with C. albicans and the respective fractions to achieve a total volume of 200 µL/well. After incubation for 24 hours or 48 hours in a humidified atmosphere (5% CO 2 ) at 37°C, the supernatants were collected and stored at −20°C until further assay.
Vitamin D Level Measurement
Vitamin D levels were measured using deidentified serum specimens from patients with Candida BSI in our hospital against anonymized serum specimens from hospitalized and healthy subjects archived in our hospital's clinical laboratory. The Roche Elecsys vitamin D commercial assay was used to determine 25-hydroxyvitamin D levels in human serum, and the assay revealed that >95% of the vitamin D (25-OHD) measured in serum was vitamin D 3 [13] . This electrochemiluminescencebased immunoassay was read on a Cobas e411 analyzer.
Recruitment and Phagocytosis Assay
Neutrophil and macrophage recruitment were assessed following intraperitoneal injection of mice with 1 × 10 6 inactivated
Candida microorganisms/mL at 4 hours and 72 hours, respectively. The peritoneal cells were extracted by injecting 4 mL of ice-cold PBS-heparin into the peritoneal cavity. After washing, cytospin of the sample extract, followed by enumeration of the cell types, was performed under microscopy. To ascertain phagocytosis and killing, peritoneal phagocytes as obtained were washed and counted in a counting chamber. The processes of phagocytosis and intracellular killing were studied in an adherent monolayer of phagocytes [14] .
Histology
The mouse kidneys were studied by light microscopy with hematoxylin and eosin and Gomori methenamine silver staining after being fixed in 4% formalin, processed and embedded in paraffin, and sectioned at thicknesses of 3 µm. Sections were assessed via light microscopy for the presence of Candida and the locations in the kidney where the organisms were present (in the glomeruli, cortex, medulla, and pelvicalyceal regions).
Stimulation and Cytokine Measurement
Spleen cells (5 × 10 5 cells/mL) obtained from mice on day 6 of infection were stimulated with heat-killed C. albicans (1 × 10 6 organisms/mL) in 96-well microtiter plates at 37°C. After 24 or 48 hours, supernatant was collected, and cytokine measurements were made using an enzyme-linked immunosorbent assay according to the instructions of the manufacturer (eBioscience, San Diego, California). Detection limits were 20 pg/mL (for interleukin 1b [IL-1b], TNF-α, and IFN-γ) and 10 pg/mL (for interleukin 17 [IL-17] and IL-10).
RNA Isolation and Quantitative Polymerase Chain Reaction (PCR) Analysis
Splenocytes were harvested from mice pretreated with 3 days of vitamin D 3 (or PBS as control) while human PBMCs were preincubated with vitamin D 3 (or PBS as control) for 30 minutes.
The effects of both low-dose (0.01 µg/mL) and high-dose (1 µg/mL) 1,25(OH) 2 D 3 were studied. The cells were then stimulated with heat-inactivated C. albicans for 4 hours. RNA was extracted from the splenocytes and PBMCs, using 500 µL of TRIzol reagent (Sigma, St. Louis, Missouri). Subsequently, 200 μL of chloroform and 500 μL of 2-propanol were used to separate the RNA from DNA and proteins. After washing with 75% ethanol, the dry RNA was dissolved in 50 μL of diethylpyrocarbonate water. To obtain complementary DNA, we reverse transcribed 1 μg of DNase-treated total RNA with oligo(dT) primers (0.01 μg/mL) in a reverse transcription PCR mixture with a total volume of 20 μL. Quantitative PCR was performed using the ABI Prism 7000 Thermocycler and SYBR Green. The primers we used are listed in the Supplementary Materials. Quantification of the PCR signals for each sample was performed by comparing the cycle threshold (Ct) values, in duplicate, for the gene of interest with the Ct values for B2M as a housekeeping gene. Mean relative messenger RNA expression was calculated using the comparative Ct method. Values are expressed as a ratio of fold increase to mRNA levels of unprimed cells.
Chromatin Immunoprecipitation (CHIP)
To investigate vitamin D receptor (VDR) binding to the IFN-γ promoter, PBMCs from healthy volunteers were or were not treated with vitamin D 3 for 30 minutes, followed by stimulation with C. albicans for 4 hours. Nuclear proteins were cross-linked to DNA with 1% formaldehyde and incubated at room temperature for 10 minutes on a rocking platform. Cross-linking was stopped by adding glycine to a final concentration of 0.2 M for 5 minutes. The cells were collected by centrifugation and washed twice with ice-cold PBS. The cell pellets were resuspended in 500 µL of sodium dodecyl sulfate lysis buffer, and the lysates were sonicated to yield DNA fragments of 200-500 bp. Cell debris was removed by centrifugation. Five percent of the sonicated chromatin was set aside for input control and the rest was divided equally into 2 tubes, one for anti-VDR antibody and the other for the control immunoglobulin G (IgG). The lysates were diluted 1:10 in ChIP dilution buffer. One microgram of anti-VDR antibody (catalog no. sc-1008; Santa Cruz, Dallas, Texas) was added to one of the tubes, and 1 μg of nonspecific IgG (catalog no. sc-2027; Santa Cruz) was added to the other, and the tubes were incubated overnight at 4°C on a rotating platform. The immunocomplexes were collected using Recombinant Protein A-Sepharose beads (Invitrogen, Frederick, Maryland). The beads were washed sequentially for 10 minutes at 4°C with rotation, using low-salt buffer, high-salt buffer, and LiCl wash buffer. The beads were finally washed twice with TE buffer, and the immune complexes were eluted using 300 µL of elution buffer at room temperature for 20 minutes with rotation. The immune complexes and the input samples were reverse cross-linked at 65°C overnight in the presence of proteinase K (Invitrogen). DNA was extracted with phenol chloroform extraction and ethanol precipitation. Real-time PCR reactions were performed using Sybr Green qPCR master mix (Applied Biosystems, Warrington, United Kingdom) with genomic primers for the BED promoter regions [15] of the gene encoding IFN-γ (Supplementary Materials), using the ABI Prism 7000 apparatus. The results were normalized with respect to the input. Nonspecific IgG results were subtracted using the formula 2
where ΔCt is calculated as Ct (ChIP DNA) -Ct (Input) , and Ct is the cycle number.
Flow Cytometry
Splenocytes were harvested and washed twice with 1 × PBS supplemented with 0.2% (w/v) bovine serum albumin, stained with CD4-APC/CD25-PE fluorochromes, and fixed and permeabilized using the FoxP3 staining kit (catalog no. 320018; Biolegend, San Diego, California). The cells were then intracellularly stained using Foxp3-Alexa Fluor 488 or isotype control and were analyzed on the BD LSRII Flow Cytometer (BD Biosciences, San Jose, California). Data analysis was performed using FlowJo software (version 7.6.5; Tree Star, Ashland, Oregon).
Statistics
Results were pooled from at least 3 sets of experiments (unless otherwise stated) and are presented as means ± standard error of the mean (SEM). Statistical analysis was performed using the Mann-Whitney U test or the paired Wilcoxon signed rank test, when relevant. P values of <.05 were considered statistically significant.
Ethics Statement
Institutional review board approval (from the Domain Specific Review Boards, National Healthcare Group, Singapore) was obtained to perform the studies involving human subjects. Ethics approval for conduct of the animal study had been attained through the Biological Resource Centre Institutional Animal Care and Use Committee (Singapore). 
RESULTS
Candidemia Patients Have Lower Vitamin D Levels
To underline the role of vitamin D in candidemia in the clinical setting, we measured 25-OHD levels in sera obtained from 28 hospitalized patients with Candida BSI and compared them to levels in anonymized sera from 75 hospitalized patients in our hospital. As shown in Figure 1 , patients with Candida BSI had significantly lower 25-OHD levels (mean [±SEM], 12.31 ± 1.69 ng/mL vs 17.04 ± 1.28 ng/mL; P = .045). The mean 25-OHD level (±SEM) measured in a cohort of 30 healthy volunteers was 20.88 ± 1.51 ng/mL, and this was significantly higher than in candidemic patients (P < .01) but was not significantly different from values for the anonymized hospitalized patients.
1,25(OH) 2 D 3 Reduces Candida Fungal Burden but Not at High Dose
In the following experiments, we assessed whether vitamin D might influence susceptibility to Candida infection in vivo. Over a treatment range of 0.001-1 μg/kg, Candida-infected mice that received 0.01 or 0.1 μg/kg of Calcijex had significantly decreased kidney fungal burden, compared with untreated mice (Figure 2A ). The weight loss trends mirrored that of fungal burden in the lower-dose vitamin D 3 -treated mice ( Figure 2B ). On the other hand, mice that received high dose of Calcijex (1 μg/kg) had increased Candida growth. Findings in histological sections of the mouse kidneys corresponded to the CFUs obtained through cultures. There were fewer germinating yeast in mice treated with 0.01 or 0.1 µg/kg of Calcijex ( Figure 2C ). In terms of overall survival ( Figure 2D ), Candida-infected . Each experiment consisted of 5 mice per condition. The experiment was repeated 3 times, and the results were pooled. C, Histological sections of kidneys from Candida-infected mice treated with 0.001-1 µg/kg of Calcijex and from untreated mice, stained with Gomori methenamine silver. D, Survival rate among Candida-infected mice treated with daily continuous low-dose Calcijex (LD Calcijex con't) or a 3-day Calcijex treatment regimen (LD Calcijex 3 days), each at a dose of 0.01 µg/kg, or with high-dose Calcijex (HD Calcijex, 1 µg/kg) for 3 days, compared with that among untreated mice (who were administered an equivolume of PBS). *P < .05, compared with the untreated group. Abbreviation: CFU, colony forming units.
mice that received 3 daily doses of 1,25(OH) 2 D 3 had increased survival, compared with untreated mice (P = .006). The administration of daily doses of vitamin D 3 (0.01 µg/kg of Calcijex intraperitoneally) did not confer an additional survival benefit, compared with the 3-day Calcijex regimen described above at the same dose (P = .5). Not unexpectedly, mice given a high dose of Calcijex (1 μg/kg) showed poor survival, consistent with the increased fungal burden observed.
Recruitment Capability and Phagocytic Function
To investigate whether vitamin D 3 might influence the influx kinetics of inflammatory cells and phagocyte function, cells were harvested from the peritoneal cavity 3 and 72 hours after intraperitoneal injection with Candida in control mice and 1,25(OH) 2 D 3 -treated mice. There was no significant difference in the recruitment capacity of neutrophils, monocytes, lymphocytes, and macrophages in mice treated with low-dose Calcijex ( Figure 3A ). In the 1,25(OH) 2 D 3 -treated group, there was a trend toward increased phagocytosis of Candida, but overall, there was no significant enhancement of neutrophil function. A marginal but significant increase in the killing of Candida was observed in macrophages extracted from mice treated with 1,25(OH) 2 D 3 ( Figure 3B ). However, the enhanced anti-Candida capabilities observed were modest and less likely to be of relevant physiological significance. 
Modulation of STAT and SOCS mRNA Transcription by Vitamin D 3
In view of the unanticipated proinflammatory response induced by 1,25(OH) 2 D 3 during Candida infection, we studied the possible mechanisms through which this response may be mediated. In particular, the STAT and SOCS pathways are known to be central mediators of the host type 1 T helper cell (Th1) response. Vitamin D 3 exerted a differential dose-related effect on SOCS3 transcription: only low-dose vitamin D 3 inhibited SOCS3 mRNA transcription. Correspondingly, STAT-3 mRNA expression was enhanced ( Figure 5A ). On the other hand, there was loss of effect of vitamin D 3 at higher doses. There was also no influence on the STAT1 and SOCS1 pathway ( Figure 5B ). These effects were seen in both the human PBMC system and in mouse splenocytes ( Figure 5C and 5D) .
VDR Binding to the Promoter Region of the Gene Encoding IFN-γ
The accentuated proinflammatory response, particularly the IFN-γ response, induced by vitamin D 3 was not mediated to a significant extent by the STAT1/SOCS1 pathway. Binding and activation of the VDR could induce its interaction with specific vitamin D response elements present in the BED promoter of the gene encoding IFN-γ [15] . Using ChIP-PCR, we showed that low-dose 1,25(OH) 2 D 3 induced increased VDR binding to the IFN-γ BED promoter during Candida infection in PBMCs ( Figure 6A ). In contrast, high-dose vitamin D 3 led to reduced binding. Cells treated with low-dose 1,25(OH) 2 D 3 had increased IFN-γ production downstream, validating the sequelae of the mechanistic modulation that we had elucidated above ( Figure 6B ).
DISCUSSION
In the present study, we showed that vitamin D 3 exerts a bimodal effect on host immune response against Candida. At low doses, vitamin D 3 conferred resistance against candidemia. On the other hand, supplementation of the host with highdose vitamin D 3 could be detrimental. The beneficial effects observed with low-dose vitamin D 3 were mediated through the enhancement of the host immune response. This was through potentiation of the proinflammatory cytokine response, among which IFN-γ, TNF-α, and IL-17 are known to have important roles in antifungal host defense [16, 17] . Mechanistically, low doses of vitamin D 3 suppressed SOCS3 at the level of mRNA transcription and correspondingly increased STAT3 activity. Furthermore, we showed that vitamin D 3 also exerted an effect upstream through increased binding to the IFN-γ promoter BED to induce IFN-γ production. The vitamin D nuclear receptor was involved in mediating these responses.
These findings are both novel and unanticipated. The reported observations to date generally describe the propensity of Figure 5 . A to D, SOCS1, SOCS3, STAT1, and STAT3 relative messenger RNA expression in mice splenocytes from Candida-infected mice treated with 0.01 μg/kg or 1 μg/kg of Calcijex and human peripheral blood mononuclear cells treated with low-dose (0.01 µg/mL) and high-dose (1 µg/mL) Calcijex. Data are expressed as fold changes relative to levels in untreated controls. *P < .05, compared with untreated controls.
vitamin D 3 to skew the immune response away from a Th1 type response toward interleukin 4-and IL-10-driven Th2 responses [3, 18] . This has been attributed to the capacity of vitamin D 3 to inhibit T-cell proliferation through suppression of interleukin 2 through the NFATp/AP-1 complex [19, 20] . Similarly, vitamin D 3 inhibits IL-12 in dendritic cells [21] . This results in suppression of not just Th1, but also Th17 inflammatory responses. We and others have attributed this partly to vitamin D 3 's capacity to downregulate transcription and expression of surface pattern-recognition receptors [11, 22] . However, many of those in vitro experiments, including our own earlier studies on the immunomodulatory effects of vitamin D 3 , had used higher doses of vitamin D 3 that, in retrospect, might be supraphysiological in vivo [23] .
On reassessment of our published data in Candida-infected human PBMCs, we observed a trend toward increased IFN-γ production with low-dose 1,25(OH) 2 D 3 and cytokine suppression at higher doses [11] . As such, our current in vivo and ex vivo results were largely consistent with our earlier observation. Besides the bimodal cytokine trends elicited in the Candidastimulated splenocytes, more important was our ability to demonstrate the corresponding sequelae of such immunomodulation by vitamin D 3 in the host, as evidenced by the fungal burden trends (both microbiologically and histologically). While the recruitment of inflammatory cells during infection and phagocytic function did not seem significantly altered, there was a marginal increase in intracellular Candida-killing capacity. We showed, in turn, that low-dose vitamin D 3 enhanced host inflammatory response most clearly through IFN-γ in the anti-Candida Th1 effector arm and likely through induction of Th17 responses. This was mediated through the suppression of SOCS3 transcription. A resultant increase in IFN-γ could be accounted by the reported capacity of SOCS3 to inhibit Th1 differentiation [24] . The corresponding upregulation of STAT3 expression is seen with the trend toward increased production of IL-17, as seen in our study.
The VDR played a central role in mediating these responses. As a member of the nuclear receptor superfamily, the VDR can be activated by low concentrations of 1,25(OH) 2 D 3 [25] . The VDR is a nuclear receptor that can act as a transcription factor to bind to specific vitamin D response elements within the regulatory regions of specific primary target genes [26] . To further account for the increased IFN-γ immunogenicity induced by vitamin D 3 , we demonstrated that low-dose vitamin D 3 exerted a more profound effect on IFN-γ production upstream. We showed that 1,25(OH) 2 D 3 induced the increased binding of VDR to the BED promoter region of the gene encoding IFN-γ and that this led to increased production of IFN-γ.
This observation of a bimodal effect suggests the differential susceptibility to modulation of the various immune targets and pathways by 1,25(OH) 2 D 3 . SOCS3 transcription, for instance, could be suppressed by low doses of 1,25(OH) 2 D 3 . However, it is only with higher doses that we saw general attenuation or even inactivation of other target genes of interest. This reasonably accounts for the differences between results of our study and those of other studies performed earlier. Most of such earlier studies on the immunomodulatory effects of 1,25(OH) 2 D 3 had been derived from in vitro studies using higher doses of 1,25(OH) 2 D 3 that might be supraphysiological. Thus, while the consensus remained in that the effects of high concentrations of 1,25(OH) 2 D 3 are largely antiinflammatory [27] , the intrinsic higher susceptibility of some immune targets (eg, SOCS3) to low levels of vitamin D 3 and the increased 1,25(OH) 2 D 3 -induced VDR binding to the IFN-γ BED promoter warrant highlighting.
The above observations are very relevant in the clinical context. Vitamin D 3 deficiency has been well described to be associated with various disease states, especially susceptibility to (control) and those that were treated with Ld VD or Hd VD were stimulated with C. albicans. Production of IFN-γ was measured in each group (n = 5 subjects). Results were pooled from 2 sets of experiments, *P < .05, compared with untreated controls.
infections [28] [29] [30] [31] , as we have also demonstrated here in the context of candidemia. However, epidemiological data studying the association between vitamin D levels, supplementation, and specific infectious diseases, such as tuberculosis and viral infections, have been inconclusive [32] [33] [34] [35] [36] [37] [38] . This may be attributable to the differences in the supplemental doses used, as our findings suggest that the immunomodulatory effect of vitamin D 3 is dose dependent. Nonetheless, the bimodal effect as demonstrated in our animal studies raises the questions about what constitutes a low dose of vitamin D 3 (with its potentially beneficial effects of supplementation) and what constitutes a higher dose of vitamin D 3 (with its perhaps excessively immunosuppressive effects) in the human host. Indeed, while a higher vitamin D 3 level with its anticipated immunosuppressive influence may be a requisite against inflammatory conditions such as multiple sclerosis or inflammatory diseases, immunomodulation at such levels may not be appropriate in the context of infections. It remains to be determined as to what ought to be the optimal physiological level of vitamin D 3 in the body, although a recent recommendation had been to increase circulating 25(OH)D 3 concentration to >75 nmol/L [39] . In light of this study, however, a more prudent approach and more-specific in vivo studies need to be conducted to answer this question.
In conclusion, we have demonstrated that patients with candidemia have lower levels of vitamin D. In turn, limited supplementation of vitamin D augments host immunity and enhances resistance against C. albicans infection. On the other hand, excessive high-dose vitamin D suppresses the host immune response. On the background of the findings of this study and the continued debate over recommendations for vitamin D supplementation [40] against morbidity and mortality risk reduction, the balance between vitamin D supplementation and potential caution against hypervitaminosis D needs to be highlighted.
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